SEE-DRUG’s major aim is to strengthen and broaden the scientific reach and socio-economic impact of the University of Patras (UPAT) through the creation of a Regional Centre of Excellence for Structural Biology that emphasizes the characterization and development of bioactive molecules with therapeutic potential. SEE-DRUG takes advantage of UPAT’s pivotal strength and growth potential of Structural Biology and combines it with high-quality, multidisciplinary scientific expertise in Chemistry, Pharmacology, Biology and Bioinformatics. The SEE-DRUG project will enable: (a) the Protein Production group to efficiently produce and characterize protein drug-targets for structural analysis and drug development efforts, (b) the Structural Biology group to perform high-resolution structure determination, through time- and cost-effective NMR-based, cutting-edge techniques, and (c) the Pharmacology group to characterize lead therapeutic molecules in a comprehensive array of in vitro, ex vivo and in vivo systems.Such a state-of-the-art centre will create a research ecosystem providing a number of positions for highly skilled scientists, engineers and for other qualified staff, and thus enhance scientific and economic growth both at a local and at a regional level, which will hopefully be sustained for years to come. It will also achieve the optimal integration of UPAT’s Structural Biology in ERA through the establishment of long-lasting partnerships, and will enhance the exchange of expertise and the building of networks with other scientists and technology end-users at a regional or local level, including the biopharmaceutical industry. Last, but not least, UPAT will provide knowledge, expertise and access to national, regional European and extra-European users or groups.